Ligustrum vicaryi L. is a hybrid of Ligustrum ovalifolium Hassk. var. aureo-marginatum and Ligustrum vulgale L., belonging to the Oleaceae family. It is often used as an ornamental shrub due to its golden leaves. However, its medical value is yet to be discovered. Recently, plant polysaccharides have attracted comprehensive attention owing to their biological properties, including immunomodulatory and antioxidant activities. This study aimed to extract, purify, and characterize the polysaccharide from the Ligustrum vicaryi L. fruit and investigate its immunomodulatory and antioxidant activities. The Ligustrum vicaryi L. fruit polysaccharide (LVFP) was obtained by ultrasonic extraction, ethanol precipitation, macroporous resin separation, and dialysis bag purification. The physicochemical properties of the LVFP were elucidated using Fourier‐transform infrared spectrometry, high‐performance ion chromatography, and high‐performance gel filtration chromatography. The results indicated that the LVFP consisted of rhamnose, arabinose, galactose, and glucose in a ratio of 1.79 : 7.55 : 4.58 : 1.54, and its molecular weight was 88,949 Da. The immunomodulatory and antioxidant activities of the LVFP were investigated using a cyclophosphamide‐ (Cy‐) induced immunosuppressed mouse model. The results demonstrated that the LVFP significantly increased spleen and thymus indexes, enhanced the phagocytic function of neutrophils, activated B and T lymphocytes, and upregulated serum levels of IL‐10 and TNF‐α. Moreover, we observed that the LVFP relieved Cy‐induced liver damage by increasing superoxide dismutase (SOD) and glutathione peroxidase (GSH‐px) levels. These results suggested that the LVFP has the immunomodulatory and antioxidant activities, therefore laying a foundation for the application of the LVFP in the pharmaceutical and functional food industries.

Although hydrazine (N₂H₄) is a versatile chemical used in many applications, it is toxic, and its leakage may pose a threat to both human health and environments. Consequently, the monitoring of N₂H₄ is significant. This study reports a one-step synthesis for coumarin-based ratiometric fluorescent probe (FP) CHAC, with acetyl as the recognition group. Selected deprotection of the acetyl group via N₂H₄ released the coumarin fluorophore, which recovered the intramolecular charge transfer process, which caused a prominent fluorescent, ratiometric response. CHAC demonstrated the advantages of high selectivity, a strong capacity for anti-interference, a low limit of detection (LOD) (0.16 μM), a large linear detection range (0–500 μM), and a wide effective pH interval (6–12) in N₂H₄ detection. Furthermore, the probe enabled quantitative N₂H₄ verifications in environmental water specimens in addition to qualitative detection of N₂H₄ in various soils and of gaseous N₂H₄. Finally, the probe ratiometrically monitored N₂H₄ in living cells having low cytotoxicity.

The dried fruits of Ligustrum lucidum Ait. are well-established in East Asian medicine for hepatoprotection. Given this ethnopharmacological precedent and their close taxonomic kinship, we hypothesized that the fruit polysaccharide of its horticultural congener, Ligustrum × vicaryi L. (LVFP), may confer analogous hepatic benefits. We assessed LVFP in a murine model of acute liver injury (ALI) induced by lipopolysaccharide and D-galactosamine (LPS/D-GalN) to test this hypothesis. LVFP pretreatment significantly mitigated hepatic pathological damage, normalized serum aminotransferases (AST, ALT), and reversed lipid peroxidation (reduced MDA, elevated SOD). Simultaneously, LVFP reduced pro-inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), and corrected lipid metabolic abnormalities (CHO, TG). To decode these phenotypic rescues, network pharmacology and molecular docking nominated a 10-gene hub signature (featuring KDR (binding energy = −8.65 kcal/mol), AKT1, GSK3B, and IL2). we further found that this signature—particularly KDR and PKM—robustly discriminates ALI from controls (AUC = 1.00; AUPR = 0.848), supporting its disease relevance. Collectively, these findings support our initial hypothesis that LVFP exerts multi-dimensional hepatoprotection.

Background: Myocardial fibrosis (MF) is a prevalent pathological condition associated with various heart diseases, such as heart failure and arrhythmias, which disrupt electrical signals and reduce pumping efficiency. This research explored the therapeutic effects and potential mechanisms of Ligustrum vicaryi L. fruit polysaccharide (LVFP) on MF.Methods: In vivo experiments, including fibrosis markers assay, echocardiography, HE staining, Sirius red staining, and Masson's trichrome staining, were performed to evaluate the therapeutic efficacy of LVFP in treating isoproterenol (ISO)-induced MF. We utilized the PharmMapper database to identify targets of LVFP, aiming to explore potential targets. Additionally, we obtained MF-related targets from the GeneCards database. We utilized Venny, a bioinformatics tool, to identify the intersection between the targets of LVFP and those related to MF. We utilized the STRING database to construct a protein interaction network for the overlapping targets and identified key targets for LVFP in treating MF through cytoHubba analysis. We conducted Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis on the intersection targets. We also examined the interaction between LVFP and the key targets using molecular docking techniques.Results: LVFP significantly inhibited fibrosis biomarker such as hydroxyproline (HYP) and decreased myocardial fibrosis level as shown by heart weight to tibia length (HW/TL) measurement when compared to ISO-treated mice. Additionally, it increased ejection fraction (EF) and fractional shortening (FS) levels. LVFP showed decreased collagen levels compared to the ISO-treated mice by histological quantification of cardiac fibrosis. Based on the monosaccharide structures of LVFP, 413 targets were identified, with 67 associated with MF. Analysis indicated that the 9 hub genes (AKT1, HSP90AA1, SRC, GSK3β, VEGFR2, RHOA, ENO1, PKM, and IL-2) play roles in MF treatment by participating in signaling pathways related to prostate cancer, lipid and atherosclerosis, and insulin resistance. Molecular docking results showed that LVFP exhibited strong binding potential to VEGFR2 (−8.65 kcal/mol), AKT1 (−7.36 kcal/mol) and GSK3β (−7.68 kcal/mol).Conclusion: LVFP shows promise as a therapeutic agent for MF, primarily through the regulation of various signaling pathways and targets. These findings provide novel insights for the treatment of MF utilizing LVFP.